Akoya Biosciences, Inc.

AT CELLCARTA WE ARE DEDICATED TO WORKING WITH OUR PARTNERS TO FURTHER THE LIMITLESS POTENTIAL OF PRECISION MEDICINE

As a global contract research organization (CRO) laboratory, we partner with our clients to address the most complex biomarker and bioanalytical challenges and deliver highly customized testing solutions. With facilities located in Canada, United States, Belgium, Australia and China, CellCarta provides the expertise needed locally to support global clinical trials.

CellCarta offers access to integrated analytical platforms in immunology (immune monitoring), histopathology, proteomics and genomics, as well as sample logistics services.

At CellCarta we are experts at assessing the immune system, whether in the context of oncology, infectious diseases, or autoimmune diseases. With a proven track record in other therapeutic areas as, such as neurological and metabolic disorders, we handle all human biological specimens and deploy relevant technologies to extract valuable information for research and diagnostic applications. We provide assay development and testing services to support a wide variety of translational research, clinical trials, and diagnostic applications.

Committed to delivering the highest quality science and innovation, CellCarta recently acquired Clinical Logistics to expand its specialty specimen logistics and kitting services and Mosaic Laboratories for multiplex immunohistochemistry assays development and deployment.

Reflecting our commitment to quality, our sites hold the appropriate accreditations to support your regulatory requirements, inNeo-Epitope Discoverycluding CAP, CLIA, ISO15189 and ISO13485.

CellCarta is privately held and majority-owned by Arsenal Capital Partners.

Ambit Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Our pipeline currently includes three programs, each aimed at the inhibition of validated kinase targets.

Our lead drug candidate, quizartinib, is a once-daily, orally-administered, potent and selective inhibitor of FMS-like tyrosine kinase 3 (FLT3), a validated target in the treatment of AML, and is currently in Phase 2b clinical development in relapsed/refractory AML patients who express the FLT3-ITD mutation (FLT3-ITD positive patients). The FLT3-ITD mutation acts like a “power switch” that causes leukemic cells, or blasts, to spread more aggressively and grow back more rapidly following chemotherapy, conferring an especially poor survival outcome. Quizartinib is designed to turn off this switch.

Our second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases.

Our third program consists of a potent and exquisitely selective small molecule compound, AC708, which inhibits the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase. This compound is in preclinical studies and has potential utility in oncology, autoimmune and inflammatory diseases. All of our drug candidates and clinical candidates have been internally discovered by us.

BioAgilytix is a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development. With laboratory locations in North Carolina’s Research Triangle Park; Cambridge, Massachusetts; San Diego, California and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states.
BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product release testing, stability testing, etc.) BioAgilytix also offers diagnostic testing services at its CLIA-certified, CAP-accredited Boston laboratory.
BioAgilytix’s team of highly experienced scientific and QA professionals ensures high-quality science, data integrity and regulatory compliance through all phases of clinical development. BioAgilytix is a trusted partner to many top global pharmaceutical and biotech companies. For more information, visit www.bioagilytix.com.

Celentyx is a human immune system focused R&D and service company specialising in immuno-oncology, inflammation and autoimmunity in vitro assays using healthy donor and patient tissues and cells.

Celentyx’s unique ImmuKnowlogy™ platform allows rapid analysis of drug action on human immune cells - from healthy donors or patients with defined clinical disease. Drawing on the World-leading expertise of Celentyx personnel, which along with our strategic relationships with the MRC Centre for Immune Regulation and the Centre for Translational Inflammation Research (at the Queen Elizabeth 'Super-hospital', Birmingham), enables the human immune system to be investigated at the highest levels of resolution.

Celentyx's ImmuKnowlogy™ services enable partners to quantify efficacy, elucidate the mechanism of action of an immunomodulatory drug, facilitate lead candidate prioritisation or identify potentially negative impact of a drug on the human immune system prior to first administration to man.

Celentyx's Novel Clinical Indication Profiling™, which applies the powerful Immuno-Profiling™ platform to reprofile (repurpose) drug candidates for diseases of the human immune system (e.g. inflammation, autoimmune disease, allergy, graft rejection, lymphoma, leukaemia), has created an increasing portfolio of valuable drug indications.

Since 1997 IBL-America has been a supplier of in-vitro diagnostic kits, antibodies and proteins for the medical device industry as well as the medical research industry. IBL-America is active in the following areas: autoimmune, brain research, endocrinology, infectious disease, neuroscience, oncology and tumor markers. IBL-America has its own technical support staff and works in conjunction with its sister company, KMI Diagnostics, to provide expert technical service and customer support. KMI Diagnostics, Inc.(www.kmidiagnostics.com) is a CLIA certified endocrinology and research laboratory specializing in hormone and neurotransmitter testing as well as correlation studies and pre-clinical trials.